U.S. Expansion Nyxoah is actively expanding in the U.S. with the Genio system and post-approval studies like BREATHE, presenting a substantial opportunity to grow domestic adoption, engage with urology/ENT clinics, and cultivate payer discussions.

Strong Revenue Momentum Q2 2026 results show double-digit sequential growth in U.S. revenue and ongoing international expansion, signaling a scalable sales model and potential for larger hospital and clinic systems to adopt Genio clinically.

Clinical Evidence Path The Genio neuromodulation approach is backed by ongoing post-market studies and long-term clinical evidence, creating a compelling case for researchers, KOLs, and payers when presenting value overruns and cost-of-OSA burden reduction.

Integrated Tech Stack Nyxoah’s adoption of enterprise tools (AWS, SAP, NetSuite, Salesforce-adjacent stack) supports scalable operations and data-driven sales enablement, enabling faster deployment to new centers and better customer success tracking.

Strategic Financing With secured financing in the recent quarter and a substantial total funding round, there is room to structure financing and reimbursement strategies with hospitals and distributors, accelerating large-scale deployments.